Barry E. Greene

This profile gathers the share dealings of Barry E. Greene across 2 companies, led by Sage Therapeutics, Inc. and Karyopharm Therapeutics Inc. The record holds 7 filings, for trades running from 16 June 2021 to 31 July 2025.

The open-market record is one-sided, with 3 purchases worth €1.8M and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants and 1 option exercise.

The median purchase comes to €499k. Clusters matter here: 1 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 31 July 2025 with a transaction in Sage Therapeutics, Inc. The latest purchase dates back some time: it was published 1,433 days ago, on 15 November 2022. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.